CoChat
Sign Up
Cited by 1,178Bipolar Disorder and TreatmentTreatment of Major DepressionSchizophrenia research and treatment

The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.

Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors

Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yücel, M., Gama, C.S., Dodd, S., Dean, B., Magalhães, P.V.S., Amminger, P., McGorry, P., Malhi, G.S.·2011·Neuroscience & Biobehavioral Reviews
DOI 10.1016/j.neubiorev.2010.10.001
Open this paper in CoChat — free account

Abstract

There is now strong evidence of progressive neuropathological processes in bipolar disorder (BD). On this basis, the current understanding of the neurobiology of BD has shifted from an initial focus on monoamines, subsequently including evidence of changes in intracellular second messenger systems and more recently to, incorporating changes in inflammatory cytokines, corticosteroids, neurotrophins, mitochondrial energy generation, oxidative stress and neurogenesis into a more comprehensive model capable of explaining some of the clinical features of BD. These features include progressive shortening of the inter-episode interval with each recurrence, occurring in consort with reduced probability of treatment response as the illness progresses. To this end, emerging data shows that these biomarkers may differ between early and late stages of BD in parallel with stage-related structural and neurocognitive alterations. This understanding facilitates identification of rational therapeutic targets, and the development of novel treatment classes. Additionally, these pathways provide a cogent explanation for the efficacy of seemingly diverse therapies used in BD, that appear to share common effects on oxidative, inflammatory and neurotrophic pathways.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neubiorev.2010.10.001

Cites

214 of 214 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. Berk, 2008, N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial, Biol. Psychiatry
  2. Berk, 2007, Antioxidant treatment of the glutathione deficiency in bipolar disorder with N-acetylcysteine: a double-blind randomised placebo controlled trial, Bipolar Disorders, 9, 8
  3. Lopez, C., Cortez, V., Palacio, C., Gallo, A., Lopera, J., Garcia, J., 2008. Effects of chronicity on the cognitive performance of patients with bipolar disorder type 1. In: ISBD Conference. Department of Psychiatry, School of Medicine, Universidad De Antioquia, Medellin, Colombia.

Cited by

Sorted by citations

See all 1,178

Related

See all

Metadata

Authors
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., Magalhães, P. V. S., Amminger, P., McGorry, P., & Malhi, G. S.
Affiliations
  • Barwon Health (AU)
  • Universidade Federal do Rio Grande do Sul (BR)
  • Mental Health Research Institute (AU)
  • Piyavate Hospital (TH)
  • The University of Melbourne (AU)
  • The University of Sydney (AU)
Corresponding author
Berk, M.
ORCID
Venue
Neuroscience & Biobehavioral Reviews
Publisher
Elsevier BV
Published
2011-01
Volume
35
Issue
3
Pages
804-817
ISSN
0149-7634 (ISSN-L)
DOI
10.1016/j.neubiorev.2010.10.001
OpenAlex
W2142476463
Cited by
1,178
References
214
Citations by year
2026: 49 · 2025: 50 · 2024: 50 · 2023: 54 · 2022: 56 · 2021: 70 · 2020: 95 · 2019: 82 · 2018: 89 · 2017: 90 · 2016: 103 · 2015: 110 · 2014: 89 · 2013: 92 · 2012: 69
FWCI
8.66
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neuroscience & Biobehavioral Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Swinburne figshare (Swinburne University of Technology) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
bipolar disorder, neuroprogression, neuroinflammation, oxidative stress, neurotrophic factors, neurotrophins, inflammatory cytokines, corticosteroids, mitochondrial bioenergetics, neurogenesis, treatment response, biomarkers, brain structural changes, neurocognitive impairment, therapeutic target
MeSH terms
Animals, Bipolar Disorder, Humans, Inflammation, Nerve Growth Factors, Cytokines, Neurotransmitter Agents, Oxidative Stress, Disease Progression, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review